Status:
COMPLETED
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
Lead Sponsor:
Yong-Kil Hong
Collaborating Sponsors:
Saint Vincent's Hospital, Korea
Incheon St.Mary's Hospital
Conditions:
Glioblastoma
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with recurrent or r...
Detailed Description
Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or placebo for the patients with recurrent or refractory Glioblastoma. The dosage of the Metformin will follow...
Eligibility Criteria
Inclusion
- Progressive or recurrent Glioblastoma conformed by histopathological or radiological diagnosis. Progressive or recurrent Glioblastoma during or after standard therapy (Temozolomide after Temozolomide and radiation therapy; Stupp regimen) after histopathological diagnosis of Glioblastoma Recurrence or progression is diagnosed according to histopathological diagnosis or revised RANO(Response Assessment in Neuro-Oncology) criteria c
- Karnofsky performance status(KPS) ≥ 60%
- Age ≥ 19 years old
- At least 4 weeks after operation or chemotherapy
- Normal in hematological finding, liver and kidney function
- Hematology ANC \> 1.500/mm³, Platelet \> 100,000/mm³, WBC \> 3×10\^9/L, Hemoglobin \> 9g/dL
- Liver function Total Bilirubin level ≤ 1.5×ULN(in case of isolated hyperbilirubinemia ≤2.5 x ULN) AST / ALT \< 2.5×ULN
- Renal function Serum creatinine ≤ 1.5mg/dL
- Be informed of the nature of the study and obtained a written informed consent
- A legal representative agrees to the trial when a subject is unable to communicate smoothly due to neurologic defect
- If a fertile woman who has been confirmed negative to a urine or blood pregnancy test within 28 days prior to the trial
Exclusion
- Pregnant or breast feeding
- Cancer history within 5 years excluding cancer in the skin cells and cervix
- Active infections within two weeks
- Leptomeningeal metastasis
- Patients diagnosed with diabetes
- Hypersensitive or intolerance to Metformin
- Patients who are currently taking Metformin, sulfonylureas, thiazolidinediones, and insulin, regardless of reason
- Other serious diseases or medical conditions that include :
- Patients who suffer from unstable heart disease despite treatment.
- Patients having a heart attack within 6 months prior to the start of trial
- Patients who suffer from severe nerve or psychosis that includes dementia or strokes.
- Patients with an uncontrolled infection
- Patient with uncontrolled hypertension, congestive heart failure, unstable angina, or incomplete arrhythmia
- Those who have participated in other clinical trials may not recover from the toxicity of the treatment.
Key Trial Info
Start Date :
November 21 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT03243851
Start Date
November 21 2016
End Date
December 31 2020
Last Update
September 9 2021
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center Korea
Ilsan, Gyeonggi-do, South Korea, 10408
2
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
3
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea, 16499
4
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea, 58128